Liver cancer remains one of the deadliest malignancies worldwide, with hepatocellular carcinoma (HCC) constituting the majority of cases. Its highly heterogeneous genetic landscape and limited treatment options pose significant challenges for clinicians. Conventional chemotherapy often fails due to drug resistance and harmful systemic side effects, underscoring the urgent need for innovative therapeutic strategies. Recent groundbreaking...











